Akeso's Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Combination Therapy for PD-(L)1 Resistant NSCLC Showcased in Oral Presentation at 2024 Asian Conference on Lung Cancer
HONG KONG,Dec. 4,2024-- Akeso,Inc. (9926.HK) ("Akeso" or the "Company") announced the results from a prospective,open-label,single-arm,multi-center phase Ib/II clinical study (AK10